Development of 111in-labeled liposomes for vulnerable atherosclerotic plaque imaging

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 115-120

  Ogawa, Mikako ^a   Umeda, Izumi O ^b   Kosugi, Mutsumi ^a   Kawai, Ayumi ^a   Hamaya, Yuka ^a   Takashima, Misato ^a   Yin, Hongxia ^c   Kudoh, Takayuki ^c   Seno, Masaharu ^c   Magata, Yasuhiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Liposome; Phosphatidylserine; SPECT

Indexed keywords

APOLIPOPROTEIN E; INDIUM 111; LIPOSOME; NITRILOTRIACETIC ACID; PC100 LIPOSOME; PC200 LIPOSOME; PHOSPHATIDYLSERINE; PS100 LIPOSOME; PS200 LIPOSOME; UNCLASSIFIED DRUG; INDIUM; LIPID; PHOSPHATIDYLCHOLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTORADIOGRAPHY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; ENCAPSULATION; FAMILIAL HYPERLIPEMIA; HISTOPATHOLOGY; IN VITRO STUDY; INCUBATION TIME; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PET SCANNER; PRIORITY JOURNAL; PROTEIN DEPLETION; RABBIT; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; ANIMAL; ATHEROSCLEROSIS; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; HUMAN; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; OBSERVER VARIATION; SCINTISCANNING; TIME;

ATHEROSCLEROSIS; LIPOSOME; PHOSPHATIDYLSERINE; SPECT;

ANIMALS; APOLIPOPROTEINS E; HUMANS; INDIUM RADIOISOTOPES; LIPIDS; LIPOSOMES; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; NITRILOTRIACETIC ACID; OBSERVER VARIATION; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLSERINES; PLAQUE, ATHEROSCLEROTIC; RABBITS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84894786216     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.123158     Document Type: Article

References (36)

1. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol. 2001;88(7B): 3J-6J.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420: 868-874.
3. 18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105: 2708-2711.
4. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med. 2004; 45: 1245-1250.
5. Zhang Z, Machac J, Helft G, et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med. 2006;6: 3.
6. 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. J Am Coll Cardiol. 2011; 57: 971-976.
7. 18F- fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48: 1818-1824.
8. 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49: 871-878.
9. Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2: 107-115.
10. Chen W, Bural GG, Torigian DA, Rader DJ, Alavi A. Emerging role of FDGPET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2009;36: 144-151.
11. 18F] fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging. 2003;30: 267-273.
12. 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol. 2012;59: 2080-2088.
13. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des. 2004;10: 2981-2989.
14. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1: 193-212.
15. Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163: 34-45.
16. Stossel TP. Phagocytosis (first of three parts). N Engl J Med. 1974;290: 717-723.
17. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta. 1986;881: 307-313.
18. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148: 2207-2216.
19. Tait JF, Smith C. Phosphatidylserine receptors: role of CD36 in binding of anionic phospholipid vesicles to monocytic cells. J Biol Chem. 1999;274: 3048-3054.
20. Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr Biol. 2001;11: R795-R805.
21. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev. 2001;50: 143-156.
22. Lindh I, Stawinski J. A general method for the synthesis of glycerophospholipids and their analogs via H-phosphonate intermediates. J Org Chem. 1989;54: 1338-1342.
23. Ogihara-Umeda I, Sasaki T, Kojima S, Nishigori H. Optimal radiolabeled liposomes for tumor imaging. J Nucl Med. 1996;37: 326-332.
24. Mauldin JP, Srinivasan S, Mulya A, et al. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J Biol Chem. 2006;281: 21216-21224.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193: 265-275.
26. Tsukada T, Rosenfeld M, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis. 1986;6: 601-613.
27. Almer G, Frascione D, Pali-Scholl I, et al. Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm. 2013;10: 175-186.
28. Bhavane R, Badea C, Ghaghada KB, et al. Dual-energy computed tomography imaging of atherosclerotic plaques in a mouse model using a liposomal-iodine nanoparticle contrast agent. Circ Cardiovasc Imaging. 2013;6: 285-294.
29. 18FFDG uptake to macrophages in vitro. J Nucl Med. 2012;53: 55-58.
30. Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 2012;13: 105-119.
31. Kimura Y, Fujii T, Ochi K, Akamune A, Hamamoto K. In vitro and in vivo effects of diethylene triamine penta-Acetic acid on the distribution of indium-111 monoclonal antibody metabolism. Eur J Nucl Med. 1992;19: 759-764.
32. Reilly R, Lee N, Houle S, Law J, Marks A. In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111. Int J Rad Appl Instrum [A]. 1992;43: 961-967.
33. Mulder WJ, Douma K, Koning GA, et al. Liposome-enhanced MRI of neointimal lesions in the ApoE-KO mouse. Magn Reson Med. 2006;55: 1170-1174.
34. Li D, Patel AR, Klibanov AL, et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging. 2010;3: 464-472.
35. Almer G, Wernig K, Saba-Lepek M, et al. Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques. Int J Nanomedicine. 2011;6: 1279-1290.
36. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4: 145-160.